Abstract 990P
Background
Hepatic arterial infusion chemotherapy (HAIC) is known to be more effective than conventional systemic chemotherapy, showing great potential in treating unresectable hepatocellular carcinoma (HCC) patients. However, there is still unclear which group can benefit more from HAIC.
Methods
191 patients with unresectable HCC undergoing HAIC from Zhongshan Hospital between May 2019 and March 2022 were retrospectively recruited. Radiomics scores were calculated based on enhanced-T1-weighted, enhanced-T2-weighted, arterial phase and delayed phase images. Clinical factors related to OS and PFS were identified by Cox regression analysis. Three different CNNs of AlexNet, ResNet, and Inception architectures were constructed on 70% of the data set and tested on the remaining 30%. Radiomics scores and clinical factors were reflected to a model eventually. Mean squared error (MSE) and time-dependent receiver operating characteristic curve were calculated for the models.
Results
The OS model included radiomics score with No. of HAIC cycles, tumor thrombus, PIVKA-II, neutrophil-lymphocyte ratio (NLR), aspartate aminotransferase (AST), gamma-glutamyltranspeptidase (γ-GT) and C-reactive protein. And the PFS model included radiomics score with No. of HAIC cycles, tumor thrombus, NLR and γ-GT. The AlexNet-OS model, ResNet-OS model, and Inception-OS model achieved the best MSE of 1.0068, 0.9023 and 0.8506, respectively. The AlexNet-PFS model, ResNet- PFS model, and Inception- PFS model achieved the best MSE of 0.6658, 0.6819 and 1.1012, respectively.
Conclusions
The present models which integrated radiomics information and clinical factors helped predict OS and PFS of unresectable HCC patients undergoing HAIC treatment.
Clinical trial identification
Editorial acknowledgement
We are very grateful to Mrs. Hailin Mi for helping us to construct the deep learning model. Hailin Mi kindly provided statistical advice for this manuscript. (Hailin Mi; Department of Computer Science and Technology, Harbin Engineering University, China)
Legal entity responsible for the study
The authors.
Funding
The National Natural Science Foundation of China (No. 81972889, Dr Yin).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1000P - Real-world clinical outcomes of cabozantinib (cabo) as a second-line (2L) treatment for advanced hepatocellular carcinoma (aHCC)
Presenter: Daniel Ahn
Session: Poster session 18
1001P - Patients’ prioritization of treatment goals in hepatocellular carcinoma (HCC): A global qualitative observational study (PERIDOT)
Presenter: Marcus-Alexander Wörns
Session: Poster session 18
1002P - Efficacy and safety of tislelizumab combined with TKIs and FOLFOX4-HAIC in conversion therapy of unresectable hepatocellular carcinoma
Presenter: Kai Tan
Session: Poster session 18
1003P - Efficacy and safety of triple combination therapy with transarterial chemoembolization (TACE), tyrosine kinase inhibitor (TKI), and immune checkpoint inhibitor (ICI) versus dual combination therapy in unresectable hepatocellular carcinoma (uHCC): A systematic review and meta-analysis
Presenter: Omar Maaño
Session: Poster session 18
1004P - Comparative efficacy of systemic sequential regorafenib after sorafenib or lenvatinib treatment failure for advanced hepatocellular carcinoma: A retrospective, multi-center, real-world study
Presenter: Danjun Song
Session: Poster session 18
1005P - Atezolizumab plus bevacizumab combined with transarterial chemoembolization and hepatic arterial infusion chemotherapy for unresectable hepatocellular carcinoma with high tumor burden
Presenter: Jiliang Qiu
Session: Poster session 18
1006P - Associations of online search trends and prescription trends for hepatocellular carcinoma drugs
Presenter: Philipp Berning
Session: Poster session 18
1007P - Network meta-analysis (NMA) of lenvatinib vs key comparators in first-line unresectable hepatocellular carcinoma (uHCC)
Presenter: David Trueman
Session: Poster session 18